Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 15:226:109411.
doi: 10.1016/j.neuropharm.2023.109411. Epub 2023 Jan 4.

Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia

Annalisa Pinna  1 , Pathik Parekh  2 , Micaela Morelli  3
Affiliations
Free article
Review

Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia

Annalisa Pinna et al. Neuropharmacology. .
Free article

Abstract

The dopamine neuronal loss that characterizes Parkinson's Disease (PD) is associated to changes in neurotransmitters, such as serotonin and adenosine, which contribute to the symptomatology of PD and to the onset of dyskinetic movements associated to levodopa treatment. The present review describes the role played by serotonin 5-HT1A receptors and the adenosine A2A receptors on dyskinetic movements induced by chronic levodopa in PD. The focus is on preclinical and clinical results showing the interaction between serotonin 5-HT1A receptors and other receptors such as 5-HT1B receptors and adenosine A2A receptors. 5-HT1A/1B receptor agonists and A2A receptor antagonists, administered in combination, contrast dyskinetic movements induced by chronic levodopa without impairing motor behaviour, suggesting that this drug combination might be a useful therapeutic approach for counteracting the PD motor deficits and dyskinesia associated with chronic levodopa treatment. This article is part of the Special Issue on "The receptor-receptor interaction as a new target for therapy".

Keywords: 5-HT(1A) receptors; A(2A) receptors; Basal ganglia; Clinical trials; Dopamine; Dyskinesia; MPTP; Parkinson's disease; Receptor interaction; zif-268.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms